Transglutaminases in fibrosis—overview and recent advances
American Journal of Physiology-Cell Physiology · 01.10.2023 · 325 (4) · C885-C894
DOI: 10.1152/ajpcell.00322.2023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.10.2023. Verfasst von Fatemeh Soltani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Transglutaminases, Hyperglycemia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: CIHR, Fonds de Recherche du Québec - Santé, Gouvernement du Canada | Canadian Institutes of Health Research.
Abstract (Originalsprache)
Transglutaminases (TGs) are a family of protein cross-linking enzymes that are capable of stiffening and insolubilizing proteins and creating protein networks, and thereby altering biological functions of proteins. Their role in fibrosis progression has been widely investigated with a focus on kidney, lung, liver, and heart where activity is triggered by various stimuli including hypoxia, inflammation, and hyperglycemia. TG2 has been considered one of the key enzymes in the pathogenesis of fibrosis mainly through transforming growth factor beta (TGF-beta) signaling and matrix cross-linking mechanisms. Although TG2 has been most widely studied in this context, the involvement of other TGs, TG1 and Factor XIII-A (FXIII-A), is beginning to emerge. This mini-review highlights the major steps taken in the TG and fibrosis research and summarizes the most recent advances and contributions of TG2, TG1, and FXIII-A to the progression of fibrosis in various animal models. Also, their mechanisms of action as well as therapeutic prospects are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
- Faculty of Dental Medicine and Oral Health Sciences (Biomedical Sciences), McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Mari T Kaartinen
Förderung
- CIHR
- Fonds de Recherche du Québec - Santé
- Gouvernement du Canada | Canadian Institutes of Health Research
Zitieren
APA
Soltani, F., & Kaartinen, M. T. (2023). Transglutaminases in fibrosis—overview and recent advances. American Journal of Physiology-Cell Physiology, 325(4), C885-C894. https://doi.org/10.1152/ajpcell.00322.2023
Vancouver
Soltani F, Kaartinen MT. Transglutaminases in fibrosis—overview and recent advances. American Journal of Physiology-Cell Physiology. 2023;325(4):C885-C894. doi:10.1152/ajpcell.00322.2023
BibTeX
@article{Soltani2023,
author = {Soltani, Fatemeh and Kaartinen, Mari T},
title = {Transglutaminases in fibrosis—overview and recent advances},
journal = {American Journal of Physiology-Cell Physiology},
year = {2023},
volume = {325},
number = {4},
pages = {C885--C894},
doi = {10.1152/ajpcell.00322.2023}
}
EUVIMED